PRQR ProQR Therapeutics N.V.
USHealthcareAs of 2026-07-09 16:00
Why PRQR matters now
ProQR Therapeutics N.V. (PRQR) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.76 with +4.76% on the session and $185.3M in market capitalization; recent performance reads 1-month +32.17% and YTD -6.44%.
The latest financial table shown here is Q1 2026, with revenue of $2.1M, net income of $-13.6M, and EPS of $-0.13. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -28.2%.
The latest indexable market news headline is "ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $3.75; recent insider activity includes Hinsch Gylvin Lykke filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.61
P/S
12.91
EV/EBITDA
-2.47
DCF Value
$-44.49
FCF Yield
-28.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.7%
Operating Margin
-345.5%
Net Margin
-339.4%
ROE
-86.5%
ROA
-46.0%
ROIC
-67.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.1M | $-13.6M | $-0.13 |
| Q4 2025 | $4.6M | $-8.8M | $-0.09 |
| FY 2025 | $15.3M | $-40.5M | $-0.38 |
| Q3 2025 | $2.9M | $-11.0M | $-0.10 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$3.63
Target (Median)
$3.75
Target Range
$2.00 - $5.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
NL
Exchange
—
Beta
0.06
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.